COVID Vaccine Maker Novavax Stock Soars 16% - Here's Why

Vandana Singh

Thu, May 8, 2025, 10:31 AM 3 min read

On Thursday, Novavax Inc. (NASDAQ:NVAX) reported first-quarter 2025 income of $667 million, compared to $94 million a twelvemonth ago, beating the consensus of $343.85 million.

Higher merchandise income for the archetypal 4th of 2025 were chiefly owed to $603 million of gross recognized with the termination of 2 Advance Purchase Agreements (APA) and related to currency received successful anterior years.

$45 million of Licensing, Royalties, & Other Revenue successful the archetypal 4th of 2025 was higher than the anterior twelvemonth owed to $40 million of Sanofi gross associated with upfront payment, milestone amortization, and outgo reimbursement.

Also Read: Trump-Era FDA Appointees Request New Trials For Novavax COVID Vaccine, Reportedly Delaying Approval Timeline

The COVID-19 vaccine shaper reported an net per stock of $2.93, a turnaround from a nonaccomplishment of $1.05, beating the Wall Street Estimate of 71 cents.

"I americium pleased with the advancement we person made successful the archetypal 4th connected our firm maturation strategy," said John Jacobs, President and Chief Executive Officer, Novavax. "We stay focused connected creating shareholder worth arsenic we beforehand our 3 priorities for the twelvemonth – optimizing our concern with Sanofi, advancing caller and existing concern opportunities and continuing the improvement of our early-stage integrated pipeline."

Nuvaxovid income reached $608 million, up from $82 cardinal a twelvemonth ago.

Cost of sales for the archetypal 4th of 2025 was $14 million, compared to $59 million in the aforesaid play successful 2024.

R&D expenses were $89 million, compared to $93 cardinal a twelvemonth ago, chiefly owed to reductions successful wide expenditures related to COVID-19 vaccine development.

SG&A expenses reached $48 million, compared to $87 million a twelvemonth ago, owed to the completion of commercialized activities and ongoing outgo simplification efforts.

Cash and equivalents were $747 cardinal arsenic of March 31, 2025, compared to $938 cardinal arsenic of December 31, 2024.

Guidance: Beginning with the 2025-2026 vaccination season, Novavax transitioned pb commercialized work of Nuvaxovid to Sanofi for prime markets.

Since Novavax relies connected Sanofi SA's (NASDAQ:SNY) income forecasts for definite gross components, these are not included successful the Full-Year 2025 Revenue Framework.

For 2025, Novavax expects to execute adjusted full gross between $975 million and $1.025 cardinal versus the statement of $724.16 cardinal and the anterior range of $300 million-$350 million.